A Method to Amplify Cardiac Stem Cells In-Vitro and In-Vivo
Joshua Hare and Konstantinos Chatzistergos
Problem
Cardiac stem cells, while highly promising as a therapy, require a tissue biopsy and a long period of growth in the laboratory.
Solution
MSCs can be used to accelerate the growth of CSCs in vitro or can be used to amplify CSCs in vivo, and may thereby eliminate the need for the tissue biopsy.
Competitive Advantage
Cardiac stem cells, while highly promising as a therapy, require a tissue biopsy and a long period of growth in the laboratory. Results shown by the University of Miami demonstrate that injections of MSCs into pig hearts cause massive proliferation of CSCs. MSCs can thus be used to accelerate the growth of CSCs in vitro or can be used to amplify CSCs in vivo, and thereby may eliminate the need for the tissue biopsy.
Applications
Accelerating the growth of Stem Cells for the treatment of patients with acquired and congenital cardiac diseases and disorders.
Patent Status
International Patent Application No.
WO2009046058
entitled, "A METHOD TO AMPLIFY CARDIAC STEM CELLS IN VITRO AND IN VIVO," was published on April 9, 2009.
Licensing Opportunity
The University of Miami is seeking collaborative research and licensing options.
About the Inventors
Dr. Joshua Hare was recruited from Johns Hopkins University, to become chief of cardiology and director of the Interdisciplinary Stem Cell Institute at the University of Miami. Trained at Harvard and Johns Hopkins Hospital, he became a highly productive scientist in the field of heart failure and cardiomyopathies, contributing an enormous amount of work in basic science and clinical research (1-4). Over many years, Dr. Hare and his laboratory put one of their major focuses on transcriptomic biomarker research (4-7), with the ultimate goal to improve diagnostic and prognostic accuracy in heart failure. In fact, his group published the first proof-of-concept study that transcriptomic biomarkers are feasible in cardiology and can be used to differentiate between the two major forms of cardiomyopathy, ischemic and non-ischemic (4).
Selected References
(1) Barouch LA, Harrison RW, Skaf MW et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002 March 21;416(6878):337-9.
(2) Amado LC, Saliaris AP, Schuleri KH et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005 August 9;102(32):11474-9.
(3) Gonzalez DR, Beigi F, Treuer AV, Hare JM. Deficient ryanodine receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in cardiomyocytes. Proc Natl Acad Sci USA 2007 December 18;104(51):20612-7.
(4) Kittleson MM, Ye SQ, Irizarry RA et al. Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation 2004 November 30;110(22):3444-51.
(5) Hare J.M. The dilated, restrictive and infiltrative cardiomyopathies. In: Zipes DP, Libby P, Bonow R, Braunwald E, editors. Braunwald's Heart Disease. 8 ed. Elsevier; 2007.
(6) Heidecker B, Hare JM. The use of transcriptomic biomarkers for personalized medicine. Heart Fail Rev 2007 March;12(1):1-11.
(7) Kittleson MM, Irizarry RA, Heidecker B, Hare J.M. Transcriptomics: Translation of Global Expression Analysis to Genomic Medicine. In: Willard H.F., Ginsburg G.S., editors. Handbook of Genomic Medicine. 1st ed. Elsevier; 2008.
(8) Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006 January;6(1):150-60.
(9) Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006 March;147(3):126-32.
